Iontophoretic warts therapy - NB Therapeutics

Drug Profile

Iontophoretic warts therapy - NB Therapeutics

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator NB Therapeutics
  • Class Gene therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Warts

Most Recent Events

  • 12 Jan 2011 Phase-II clinical trials in Warts in USA (Transdermal)
  • 12 Jan 2011 Iontophoretic warts therapy is available for licensing in USA, Canada, European Union, Australia, Japan as of 12 Jan 2011. http://www.nitricbio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top